Physician profile
Daniel C Voglewede
NPI 1588636633
$124,964.09
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,709 · 2021: $22K · 2022: $46K · 2023: $32K · 2024: $13.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $6,671 · Food and Beverage: $4,770 · Travel and Lodging: $4,246 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,073.00 |
| Consulting Fee | $6,670.72 |
| Food and Beverage | $4,770.40 |
| Travel and Lodging | $4,246.32 |
| Education | $147.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36,033.32 | 2019-2023 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $32,362.25 | 2019-2023 | |
| Myovant Sciences INC. | $18,532.36 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $13,963.93 | 2019-2023 | Provenge |
| Astellas Pharma US INC | $8,047.00 | 2019-2023 | Xtandi, Myrbetriq |
| Pfizer INC. | $3,272.44 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,072.81 | 2022-2023 | Lynparza |
| Janssen Research & Development, LLC | $2,525.00 | 2021-2022 | |
| Integra Gpo, LLC | $1,697.81 | 2019 | |
| Janssen Scientific Affairs, LLC | $1,100.00 | 2021 | |
| Amgen INC. | $544.63 | 2019-2023 | Xgeva, Prolia |
| Sun Pharmaceutical Industries INC. | $383.73 | 2019-2023 | Yonsa |
| Progenics Pharmaceuticals, INC. | $383.54 | 2022-2023 | Pylarify |
| Verity Pharmaceuticals INC. | $303.20 | 2021-2023 | Trelstar |
| Axonics, INC. | $265.96 | 2021-2023 | Axonics |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $261.65 | 2023 | Orgovyx |
| Merck Sharp & Dohme LLC | $258.53 | 2021-2023 | Lynparza, Keytruda |
| Urogen Pharma, INC. | $251.04 | 2021 | |
| Tolmar, INC. | $241.08 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $221.81 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $201.71 | 2021-2023 | Myrisk, Prolaris |
| Boston Scientific Corporation | $193.26 | 2019-2024 | Rezum Generator |
| Novartis Pharmaceuticals Corporation | $189.93 | 2022-2023 | |
| Abbvie INC. | $143.03 | 2019-2023 | Lupron Depot |
| Janssen Products, LP | $85.00 | 2019 | |
| Foundation Medicine, INC. | $74.72 | 2021-2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Telix Pharmaceuticals | $70.64 | 2022-2023 | Illuccix |
| Blue Earth Diagnostics | $69.23 | 2019-2022 | |
| Astellas Pharma Global Development | $65.00 | 2020 | |
| Calyxo, INC. | $54.86 | 2023 | Cvac Aspiration System |
| Caldera Medical, INC | $50.71 | 2023 | Desara |
| Genzyme Corporation | $31.41 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Voglewede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.